221 related articles for article (PubMed ID: 31374478)
1. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
Lai H; Zeng D; Liu C; Zhang Q; Wang X; Chen T
Biomaterials; 2019 Oct; 219():119377. PubMed ID: 31374478
[TBL] [Abstract][Full Text] [Related]
2. X-ray sensitive selenium-containing Ru complexes sensitize nasopharyngeal carcinoma cells for radio/chemotherapy.
Shi C; Yuan Z; Liu T; Chan L; Chen T; Zhao J
J Mater Chem B; 2023 Jun; 11(24):5607-5618. PubMed ID: 37170629
[TBL] [Abstract][Full Text] [Related]
3. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
5. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.
Zamai L; Ahmad M; Bennett IM; Azzoni L; Alnemri ES; Perussia B
J Exp Med; 1998 Dec; 188(12):2375-80. PubMed ID: 9858524
[TBL] [Abstract][Full Text] [Related]
6. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
Int J Cancer; 2013 Oct; 133(7):1643-52. PubMed ID: 23504627
[TBL] [Abstract][Full Text] [Related]
8. Down regulation of TRAIL and FasL on NK cells by Cyclosporin A in renal transplantation patients.
Zhang Y; Cheng G; Xu ZW; Li ZL; Song CJ; Li Q; Chen LH; Yang K; Yang AG; Jin BQ
Immunol Lett; 2013 Apr; 152(1):1-7. PubMed ID: 23523711
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment.
Chen Q; He L; Li X; Xu L; Chen T
Biomaterials; 2022 Feb; 281():121371. PubMed ID: 35063740
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
[TBL] [Abstract][Full Text] [Related]
11. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
12. Selenium-ruthenium complex blocks H1N1 influenza virus-induced cell damage by activating GPx1/TrxR1.
Li Y; Chen D; Su J; Chen M; Chen T; Jia W; Zhu B
Theranostics; 2023; 13(6):1843-1859. PubMed ID: 37064873
[No Abstract] [Full Text] [Related]
13. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.
Kajitani K; Tanaka Y; Arihiro K; Kataoka T; Ohdan H
Breast Cancer Res Treat; 2012 Jul; 134(1):139-55. PubMed ID: 22261932
[TBL] [Abstract][Full Text] [Related]
15. Activated NK cells kill hepatic stellate cells via p38/PI3K signaling in a TRAIL-involved degranulation manner.
Li T; Yang Y; Song H; Li H; Cui A; Liu Y; Su L; Crispe IN; Tu Z
J Leukoc Biol; 2019 Apr; 105(4):695-704. PubMed ID: 30748035
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer activity and mechanistic features of a NK cell activating molecule.
Kim HR; Lee KH; Park SJ; Kim SY; Yang YK; Tae J; Kim J
Cancer Immunol Immunother; 2009 Oct; 58(10):1691-700. PubMed ID: 19259669
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of Human Hepatic Intrasinusoidal CD56
Hwang S; Han J; Baek JS; Tak E; Song GW; Lee SG; Jung DH; Park GC; Ahn CS; Kim N
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925759
[TBL] [Abstract][Full Text] [Related]
18. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
Eur J Immunol; 2013 Jan; 43(1):249-57. PubMed ID: 22996291
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death.
Kim HR; Kim K; Lee KH; Kim SJ; Kim J
Clin Exp Immunol; 2008 May; 152(2):336-44. PubMed ID: 18336591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
